Home Magazines Editors-in-Chief FAQs Contact Us

Perspective of the β-blockers for the patients with diabetes and heart failure 


PDF Full Text

Abstract

Patients with diabetes and heart failure have been increasing due to Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study.β-blockers showed significantly suppressed cardiovascular events in the strict glycemic control group. Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i)seem to be beneficial for diabetes and heart failure. Clinical efficacy of β-blockers would be suggested from three studies including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME)trial, Canagliflozin cardioVascular Assessment Study (CANVAS)and Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study. Further discussion will be expected with research in detail.

Keywords

Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study, The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, sodium–glucose cotransporter 2 (SGLT2) inhibitors

Testimonials